Pfizer Inc Stock EBITDA

PFE Stock

USD 25.13 0.19 0.76%

Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.

		Last Reported	Projected for Next Year
	EBITDA	9.6 B	15.4 B

The current year's EBITDA is expected to grow to about 15.4 B.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pfizer Inc Company EBITDA Analysis

Pfizer's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Pfizer EBITDA

9.56 B

Most of Pfizer's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pfizer EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Pfizer is extremely important. It helps to project a fair market value of Pfizer Stock properly, considering its historical fundamentals such as EBITDA. Since Pfizer's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pfizer's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pfizer's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.77	0.82	0.77	0.54	0.98	0.64	0.35	0.87	0.84	0.87	0.3	0.91	0.91	0.88	0.79	-0.61	0.32	0.44	0.48	0.06	0.54	-0.28	0.08	0.21	-0.14	0.45	-0.36
Total Stockholder Equity	0.77		0.37	0.55	0.72	0.68	0.86	0.21	0.55	0.92	0.62	0.59	0.81	0.81	0.48	0.78	-0.43	0.26	0.29	0.27	-0.07	0.34	-0.15	0.09	-0.04	-0.17	0.28	0.01
Net Debt	0.82	0.37		0.79	0.11	0.88	0.15	0.51	0.81	0.58	0.8	-0.19	0.68	0.68	0.96	0.68	-0.7	0.23	0.46	0.62	0.42	0.68	-0.47	0.06	0.55	-0.13	0.62	-0.7
Retained Earnings	0.77	0.55	0.79		0.13	0.76	0.28	0.28	0.54	0.63	0.92	0.01	0.78	0.78	0.8	0.73	-0.95	0.15	0.68	0.64	0.21	0.93	-0.68	0.24	0.32	-0.54	0.46	-0.41
Net Receivables	0.54	0.72	0.11	0.13		0.46	0.73	0.05	0.41	0.72	0.35	0.42	0.52	0.52	0.25	0.46	0.01	0.39	0.04	0.27	-0.23	-0.08	-0.01	-0.05	-0.14	-0.04	-0.04	0.16
Total Liab	0.98	0.68	0.88	0.76	0.46		0.55	0.46	0.89	0.8	0.84	0.2	0.9	0.9	0.91	0.81	-0.64	0.38	0.38	0.5	0.1	0.56	-0.25	0.05	0.33	-0.08	0.45	-0.42
Total Current Assets	0.64	0.86	0.15	0.28	0.73	0.55		0.03	0.38	0.71	0.38	0.85	0.7	0.7	0.29	0.53	-0.17	0.3	0.09	0.0	-0.35	0.04	0.11	0.03	-0.28	0.02	-0.03	0.33
Short Term Debt	0.35	0.21	0.51	0.28	0.05	0.46	0.03		0.43	0.37	0.2	-0.21	0.43	0.43	0.32	0.65	-0.37	0.48	-0.39	0.18	0.04	0.25	0.03	-0.18	0.86	-0.09	0.18	-0.45
Intangible Assets	0.87	0.55	0.81	0.54	0.41	0.89	0.38	0.43		0.67	0.73	0.05	0.68	0.68	0.82	0.64	-0.36	0.24	0.24	0.45	0.18	0.32	-0.11	-0.23	0.35	0.05	0.56	-0.49
Property Plant Equipment	0.84	0.92	0.58	0.63	0.72	0.8	0.71	0.37	0.67		0.72	0.33	0.87	0.87	0.65	0.9	-0.55	0.39	0.31	0.51	0.09	0.47	-0.26	0.04	0.18	-0.16	0.35	-0.15
Accounts Payable	0.87	0.62	0.8	0.92	0.35	0.84	0.38	0.2	0.73	0.72		0.04	0.76	0.76	0.86	0.71	-0.78	0.07	0.69	0.69	0.26	0.8	-0.62	0.07	0.26	-0.41	0.58	-0.38
Short Term Investments	0.3	0.59	-0.19	0.01	0.42	0.2	0.85	-0.21	0.05	0.33	0.04		0.39	0.39	-0.07	0.16	0.06	0.06	-0.06	-0.31	-0.54	-0.17	0.33	0.08	-0.5	0.1	-0.23	0.55
Capital Stock	0.91	0.81	0.68	0.78	0.52	0.9	0.7	0.43	0.68	0.87	0.76	0.39		1.0	0.72	0.9	-0.73	0.57	0.28	0.46	-0.16	0.59	-0.25	0.08	0.24	-0.28	0.15	-0.15
Common Stock	0.91	0.81	0.68	0.78	0.52	0.9	0.7	0.43	0.68	0.87	0.76	0.39	1.0		0.72	0.9	-0.73	0.57	0.28	0.46	-0.16	0.59	-0.25	0.08	0.24	-0.28	0.15	-0.15
Long Term Debt	0.88	0.48	0.96	0.8	0.25	0.91	0.29	0.32	0.82	0.65	0.86	-0.07	0.72	0.72		0.67	-0.67	0.21	0.59	0.61	0.42	0.65	-0.49	0.14	0.35	-0.08	0.61	-0.61
Good Will	0.79	0.78	0.68	0.73	0.46	0.81	0.53	0.65	0.64	0.9	0.71	0.16	0.9	0.9	0.67		-0.73	0.51	0.17	0.54	0.09	0.63	-0.31	-0.03	0.5	-0.27	0.3	-0.24
Treasury Stock	-0.61	-0.43	-0.7	-0.95	0.01	-0.64	-0.17	-0.37	-0.36	-0.55	-0.78	0.06	-0.73	-0.73	-0.67	-0.73		-0.25	-0.54	-0.62	-0.17	-0.97	0.65	-0.24	-0.42	0.56	-0.3	0.32
Current Deferred Revenue	0.32	0.26	0.23	0.15	0.39	0.38	0.3	0.48	0.24	0.39	0.07	0.06	0.57	0.57	0.21	0.51	-0.25		-0.37	0.21	-0.44	0.06	0.08	-0.15	0.31	-0.17	-0.52	0.05
Net Tangible Assets	0.44	0.29	0.46	0.68	0.04	0.38	0.09	-0.39	0.24	0.31	0.69	-0.06	0.28	0.28	0.59	0.17	-0.54	-0.37		0.43	0.49	0.66	-0.66	0.49	-0.24	-0.23	0.58	-0.34
Total Permanent Equity	0.48	0.27	0.62	0.64	0.27	0.5	0.0	0.18	0.45	0.51	0.69	-0.31	0.46	0.46	0.61	0.54	-0.62	0.21	0.43		0.36	0.67	-0.73	-0.16	0.46	-0.51	0.3	-0.32
Long Term Debt Total	0.06	-0.07	0.42	0.21	-0.23	0.1	-0.35	0.04	0.18	0.09	0.26	-0.54	-0.16	-0.16	0.42	0.09	-0.17	-0.44	0.49	0.36		0.33	-0.47	0.14	0.26	0.21	0.77	-0.58
Capital Surpluse	0.54	0.34	0.68	0.93	-0.08	0.56	0.04	0.25	0.32	0.47	0.8	-0.17	0.59	0.59	0.65	0.63	-0.97	0.06	0.66	0.67	0.33		-0.75	0.24	0.39	-0.56	0.42	-0.36
Deferred Long Term Liab	-0.28	-0.15	-0.47	-0.68	-0.01	-0.25	0.11	0.03	-0.11	-0.26	-0.62	0.33	-0.25	-0.25	-0.49	-0.31	0.65	0.08	-0.66	-0.73	-0.47	-0.75		-0.15	-0.26	0.66	-0.35	0.31
Long Term Investments	0.08	0.09	0.06	0.24	-0.05	0.05	0.03	-0.18	-0.23	0.04	0.07	0.08	0.08	0.08	0.14	-0.03	-0.24	-0.15	0.49	-0.16	0.14	0.24	-0.15		-0.25	0.07	0.13	-0.33
Short Long Term Debt	0.21	-0.04	0.55	0.32	-0.14	0.33	-0.28	0.86	0.35	0.18	0.26	-0.5	0.24	0.24	0.35	0.5	-0.42	0.31	-0.24	0.46	0.26	0.39	-0.26	-0.25		-0.28	0.25	-0.56
Cash And Equivalents	-0.14	-0.17	-0.13	-0.54	-0.04	-0.08	0.02	-0.09	0.05	-0.16	-0.41	0.1	-0.28	-0.28	-0.08	-0.27	0.56	-0.17	-0.23	-0.51	0.21	-0.56	0.66	0.07	-0.28		0.11	0.01
Net Invested Capital	0.45	0.28	0.62	0.46	-0.04	0.45	-0.03	0.18	0.56	0.35	0.58	-0.23	0.15	0.15	0.61	0.3	-0.3	-0.52	0.58	0.3	0.77	0.42	-0.35	0.13	0.25	0.11		-0.67
Net Working Capital	-0.36	0.01	-0.7	-0.41	0.16	-0.42	0.33	-0.45	-0.49	-0.15	-0.38	0.55	-0.15	-0.15	-0.61	-0.24	0.32	0.05	-0.34	-0.32	-0.58	-0.36	0.31	-0.33	-0.56	0.01	-0.67

Click cells to compare fundamentals

Pfizer EBITDA Historical Pattern

Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pfizer ebitda as a starting point in their analysis.

Pfizer EBITDA

Timeline

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Pfizer

Ebitda Over Time

Pfizer Ebitda

Ebitda

15.36 Billion

At present, Pfizer's EBITDA is projected to increase significantly based on the last few years of reporting.

According to the company disclosure, Pfizer Inc reported earnings before interest,tax, depreciation and amortization of 9.56 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 145.15% lower than that of the firm.

Pfizer EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.

Pfizer is currently under evaluation in ebitda category among its peers.

Pfizer ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.

Environmental

Governance

Social

Pfizer Institutional Holders

Institutional Holdings refers to the ownership stake in Pfizer that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pfizer's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pfizer's value.

		Shares
Capital World Investors	2024-09-30	53.7 M
Bank Of America Corp	2024-06-30	52.4 M
Amundi	2024-06-30	50.2 M
Legal & General Group Plc	2024-06-30	46.6 M
Bank Of New York Mellon Corp	2024-06-30	41.9 M
Ubs Asset Mgmt Americas Inc	2024-09-30	38.1 M
Jpmorgan Chase & Co	2024-06-30	37.2 M
Goldman Sachs Group Inc	2024-06-30	34.9 M
Dimensional Fund Advisors, Inc.	2024-09-30	33.4 M
Vanguard Group Inc	2024-09-30	516.2 M
Blackrock Inc	2024-06-30	424.4 M

Pfizer Fundamentals

	Return On Equity	0.0454
	Return On Asset	0.0331
	Profit Margin	0.07 %
	Operating Margin	0.33 %
	Current Valuation	198 B
	Shares Outstanding	5.67 B
	Shares Owned By Insiders	0.04 %
	Shares Owned By Institutions	67.68 %
	Number Of Shares Shorted	61.87 M
	Price To Earning	9.48 X
	Price To Book	1.53 X
	Price To Sales	2.38 X
	Revenue	58.5 B
	Gross Profit	66.23 B
	EBITDA	9.56 B
	Net Income	2.13 B
	Cash And Equivalents	2.85 B
	Cash Per Share	6.44 X
	Total Debt	75.04 B
	Debt To Equity	0.40 %
	Current Ratio	1.59 X
	Book Value Per Share	16.29 X
	Cash Flow From Operations	8.7 B
	Short Ratio	1.83 X
	Earnings Per Share	0.75 X
	Price To Earnings To Growth	0.18 X
	Target Price	32.55
	Number Of Employees	88 K
	Beta	0.62
	Market Capitalization	141.33 B
	Total Asset	226.5 B
	Retained Earnings	118.35 B
	Working Capital	(4.46 B)
	Current Asset	43.8 B
	Current Liabilities	29.4 B
	Annual Yield	0.07 %
	Five Year Return	3.60 %
	Net Asset	226.5 B
	Last Dividend Paid	1.67

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Pfizer Piotroski F Score and Pfizer Altman Z Score analysis.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.98)

Dividend Share

1.67

Earnings Share

0.75

Revenue Per Share

10.493

Quarterly Revenue Growth

0.312

The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pfizer Inc Stock EBITDA

Pfizer Inc Company EBITDA Analysis

EBITDA

Revenue

-

Basic Expenses

Current Pfizer EBITDA

Pfizer EBITDA Driver Correlations

Pfizer EBITDA Historical Pattern

Pfizer Ebitda

Ebitda

15.36 Billion

Pfizer EBITDA Peer Comparison

Pfizer ESG Sustainability

Pfizer Institutional Holders

Pfizer Fundamentals

About Pfizer Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY